Recent Quotes
My Watchlist
Indicators
Local Stocks
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Lyra Therapeutics Inc (NQ: LYRA )

0.3076 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 26, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Lyra Therapeutics Inc

< Previous 1 2 3 Next >
Lyra Therapeutics Stock: A Deep Dive Into Analyst Perspectives (4 Ratings)
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
Where Lyra Therapeutics Stands With Analysts
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
It's time to start the day with a breakdown of the biggest pre-market stock movers traders need to keep an eye on for Tuesday! 
Via InvestorPlace
Dow Surges Over 100 Points; EyePoint Pharmaceuticals Shares Plunge
Via Benzinga
Topics Stocks
Exposures US Equities
What 4 Analyst Ratings Have To Say About Lyra Therapeutics
Via Benzinga
Lyra Therapeutics: Q1 Earnings Insights
Via Benzinga
Lyra Therapeutics's Return On Capital Employed Insights
Via Benzinga
Crude Oil Gains 1%; TreeHouse Foods Shares Fall After Q1 Results
Via Benzinga
Exposures Fossil Fuels
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
DJT Stock: Trump Media Fires Accounting Firm, Hires Replacement After SEC Charges
Trump Media & Technology stock is up on Monday as DJT investors react to the company naming a new auditor as its old one faces SEC charges. 
Via InvestorPlace
Topics Government Regulatory Compliance
Exposures Legal Political Regulatory
ZK Stock IPO: When Does Zeekr Go Public? What Is the Zeekr IPO Price Range?
Zeekr is planning an IPO this week that will have the Chinese EV company pricing shares of ZK stock between $18 and $21 per share. 
Via InvestorPlace
Topics Initial Public Offering
Exposures Securities Market
Nasdaq Jumps 100 Points; Tyson Foods Sales Miss Views
Via Benzinga
Topics Earnings
Exposures Financial
Lyra Therapeutics: Q2 Earnings Insights
  Lyra Therapeutics (NASDAQ:LYRA) reported its Q2 earnings results on Tuesday, August 9, 2022 at 07:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
Warren Buffett Just Gave Up on Paramount (PARA) Stock
Paramount Global stock is on the move Monday after Warren Buffett revealed he sold all of the PARA shares owned by Berkshire Hathaway. 
Via InvestorPlace
Why Is Lyra Therapeutics (LYRA) Stock Down 90% Today?
Lyra Therapeutics stock is falling hard with heavy trading on Monday after the company reported a failed Phase 3 clinical trial. 
Via InvestorPlace
Why Lyra Therapeutics Stock Is Down 93% Today
Lyra Therapeutics shares are trading lower by 93% to $0.30 during Monday's session. The company announced the ENLIGHTEN 1 trial did not meet its primary endpoint. 
Via Benzinga
LYRA Stock Earnings: Lyra Therapeutics Misses EPS, Beats Revenue for Q1 2024
LYRA stock results show that Lyra Therapeutics missed analyst estimates for earnings per share but beat on revenue for the first quarter of 2024. 
Via InvestorPlace
LYRA Stock Earnings: Lyra Therapeutics Beats EPS, Misses Revenue for Q4 2023
LYRA stock results show that Lyra Therapeutics beat analyst estimates for earnings per share but missed on revenue for the fourth quarter of 2023. 
Via InvestorPlace
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For August 31, 2023
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
Stocks That Hit 52-Week Lows On Monday
  On Monday, 89 stocks made new 52-week lows. 
Via Benzinga
Why Surgalign Holdings Shares Are Trading Lower By Around 75%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Gainers Airspan Networks Holdings Inc. (NYSE: MIMO) shares gained 79.5% to $0.2740. 
Via Benzinga
Important Biotech Catalysts For September 13, 2022 - End Of The Day Summary
Via Benzinga
Lyra's Mid-Stage Chronic Rhinosinusitis Candidate Study Progressed, Shares Fall
Lyra Therapeutics (NASDAQ: LYRA) advanced into its Part 2 of the Phase 2 BEACON clinical trial of LYR-220 in adults with chronic rhinosinusitis (CRS) who have had a prior sinus surgery. 
Via Benzinga
Stocks That Hit 52-Week Lows On Thursday
  During Thursday's trading, 138 companies set new 52-week lows. 
Via Benzinga
Important Biotech Catalysts For September 8, 2022 - End Of The Day Summary
Via Benzinga
Stocks That Hit 52-Week Lows On Wednesday
  During Wednesday's session, 107 stocks hit new 52-week lows. 
Via Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
Gainers Biophytis (NASDAQ:BPTS) stock moved upwards by 15.8% to $0.95 during Monday's after-market session. The company's market cap stands at $15.5 million. 
Via Benzinga
< Previous 1 2 3 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.